Lanopepden

Lanopepden (GSK 1322322) is a peptidyl peptidase (PDF) inhibitor. Lanopepden inhibits PDF activity, preventing bacterial protein synthesis, thereby exerting antibacterial activity. Lanopepden is primarily effective against Gram-positive bacteria. Lanopepden is used in the study of acute bacterial skin and skin structure infections[1].

Product Specifications

CAS Number

[1152107-25-9]

Product Name Alternative

GSK 1322322

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Lanopepden.html

Purity

98.62

Solubility

DMSO : 30 mg/mL (ultrasonic)

Smiles

FC1=C(N2CCN(CCOC3)[C@@]3([H])C2)N=C(C)N=C1NNC([C@H](CC4CCCC4)CN(C=O)O)=O

Molecular Formula

C22H34FN7O4

Molecular Weight

479.55

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Peyrusson F, et al. Cellular pharmacokinetics and intracellular activity of the novel peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus laboratory and clinical strains with various resistance phenotypes: studies with human THP-1 monocytes and J774 murine macrophages. Antimicrob Agents Chemother. 2015 Sep;59 (9) :5747-60.